These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts). Dean J; Schechter AN N Engl J Med; 1978 Oct; 299(16):863-70. PubMed ID: 692579 [No Abstract] [Full Text] [Related]
9. Seeking a way to alleviate sickle cell disease. Mitka M JAMA; 2002 Oct 23-30; 288(16):1970. PubMed ID: 12387636 [No Abstract] [Full Text] [Related]
10. The molecular basis of antisickling agents. Franklin IM; Huehns ER Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123 [No Abstract] [Full Text] [Related]
11. A view of the current status of antisickling therapy. Brewer GJ Am J Hematol; 1976; 1(1):121-8. PubMed ID: 790948 [No Abstract] [Full Text] [Related]
12. The treatment of sickle cell disease. A historical and chronological literature review of the therapies applied since 1910. Aluoch JR Trop Geogr Med; 1984 Dec; 36(4):S1-26. PubMed ID: 6396910 [TBL] [Abstract][Full Text] [Related]
13. The role of hydroxyurea in sickle cell disease. Halsey C; Roberts IA Br J Haematol; 2003 Jan; 120(2):177-86. PubMed ID: 12542474 [No Abstract] [Full Text] [Related]
14. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease? Segel GB; Simon W; Lichtman MA Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473 [No Abstract] [Full Text] [Related]
15. Pathophysiologically based drug treatment of sickle cell disease. Steinberg MH Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854 [TBL] [Abstract][Full Text] [Related]